Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq Under the Symbol "FTRP"
July 23 2021 - 7:50AM
Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field
Trip" or the “Company”), a global leader in the development and
delivery of psychedelic therapies, announced today that it has
received conditional approval from The NASDAQ Stock Market LLC
(“NASDAQ”) to list its issued and outstanding common shares on the
NASDAQ Global Select Market. Final approval of the listing is
subject to the Company fulfilling any remaining conditions as
required by NASDAQ. The Company expects to satisfy all of the
requirements and will issue a statement once a trading date has
been confirmed by NASDAQ. The Company’s common stock will continue
to trade in Canada on the TSX Exchange under its current symbol
FTRP; and until the NASDAQ listing, in the U.S. on the OTCQX under
its current symbol, FTRPF. Concurrent with the listing of Field
Trip’s common shares on NASDAQ, they will cease to be quoted on the
OTCQX.
“The anticipated listing of our stock on the
Nasdaq is a key milestone in our evolution as a publicly-traded
company,” said Joseph del Moral, Field Trip’s CEO. “We believe this
anticipated listing will improve liquidity by enabling more
investors to participate in our growth, and ultimately enhance
long-term shareholder value. This is a critical time for us to
increase our visibility in the marketplace, as we continue our work
building a world-class and disruptive company at the forefront of
the psychedelics industry.”
Mujeeb Jafferi, Field Trip’s COO added,
“Psychedelics are experiencing a once-in-a-lifetime renaissance, as
evidenced by the increasing support the industry is garnering from
scientists, regulators and investors alike. We are proud to have
established a leadership position in the industry at this exciting
time and remain laser-focused on our drug development program
advancing work on FT-104, our next generation psychedelic molecule,
and the continued rollout of our Field Trip Health clinics
business, which is bringing much-needed psychedelic therapies to
those in need.”
The Company's listing on NASDAQ remains subject
to satisfaction of all applicable listing and regulatory
requirements, including, but not limited to, the declaration of
effectiveness of the Company's Form 40-F Registration Statement
registering the Common Shares with the United States Securities and
Exchange Commission (SEC). The Company has already completed the
process to ensure its Shares are eligible for electronic clearing
and settlement through the Depository Trust Company (DTC).
About Field Trip Health Ltd.
Field Trip is a global leader in the development
and delivery of psychedelic therapies. With our Field Trip
Discovery division leading the development of the next generation
of psychedelic molecules and conducting advanced research on
plant-based psychedelics and our Field Trip Health division
building centers for psychedelic therapies opening across North
America and Europe along with the digital and technological tools
that will enable massive scale, we help people in need with a
simple, evidence-based way to heal and heighten engagement with the
world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
For further information, contact Ronan Levy,
Executive Chairman and a Director at Field Trip, at 1 (833)
833-1967.
Cautionary Note Regarding Forward-Looking
Information.
This release includes forward-looking
information within the meaning of Canadian securities laws
regarding Field Trip and its business. Often but not always,
forward-looking information can be identified by the use of words
such as "expect", "intends", "anticipated", "believes" or
variations (including negative variations) of such words and
phrases, or state that certain actions, events or results "may",
"could", "would" or "will" be taken, occur or be achieved. Such
statements are based on the current expectations and views of
future events of the management of Field Trip, and are based on
assumptions and subject to risks and uncertainties. Although the
management of Field Trip believes that the assumptions underlying
these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this
release may not occur and could differ materially as a result of
known and unknown risk factors and uncertainties affecting the
companies, including risks regarding the SEC’s declaration of
effectiveness of the registration statement and the related listing
of our common shares on NASDAQ, the timing and results of its
research and development programs, approval of phase 1 human
trials, if any, the risk that future clinical studies may not
proceed as expected or may produce unfavorable results, the opening
of additional clinics, the COVID-19 epidemic, the medical clinic
industry, market conditions, economic factors, management's ability
to manage and to operate the business and the equity markets
generally. Although Field Trip has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events
or results to differ from those anticipated, estimated or intended.
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. No forward-looking
statement can be guaranteed. Except as required by applicable
securities laws, forward-looking statements speak only as of the
date on which they are made and Field Trip does not undertake any
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, nor the OTC Markets have approved the
contents of this release or accept responsibility for the adequacy
or accuracy of this release.
Media contacts:Rachel MoskowitzAutumn
Communications202-276-7881press@fieldtriphealth.com
Nick Opich / McKenna MillerKCSA Strategic
Communications212-896-1206 /
347-487-6197press@fieldtriphealth.com
Investor contacts:Elizabeth BarkerKCSA
Strategic Communications212-896-1203ebarker@kcsa.com
SOURCE Field Trip Health Ltd.
Field Trip Health (TSX:FTRP.WT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Field Trip Health (TSX:FTRP.WT)
Historical Stock Chart
From Sep 2023 to Sep 2024